Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial
National Institute of Allergy and Infectious Diseases
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial
Ruchika Dehinwal, Nirajan Puri, Hannah Levine, Wilbur H. Chen et al.
Journal
The Lancet Infectious Diseases
Topics
Vibrio bacteria research studies
article
Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial
Ruchika Dehinwal, Nirajan Puri, Hannah Levine, Wilbur H. Chen, Stephen R. Walsh, Lena Carr, Akina Osaki, Jun Bai Park Chang, Michaël Desjardins, Damien Slater, Amy C Sherman, Matthew K. Waldor, Carole J. Kuehl, Deborah R. Leitner, Alisse Hannaford, Steven Piantadosi, Lindsey Robert Baden, August Heithoff, Bonnie Piantadosi, Bryan Wang, Emily Sullivan, Kimberly Dufresne, J. B. Harris, L Parisi, Alexander A. Morano, Aidan Eustace, Elliot Hammerness, George I Balazs, Xiaofang Li, Masataka Suzuki, Katherine G Dailey
article en
Abstract
No abstract available for this paper.
Publication Tag
The Lancet Infectious Diseases
Institutions
University of Maryland, Baltimore (US), Brigham and Women's Hospital (US), Harvard University (US), Massachusetts General Hospital (US), Centre Hospitalier de l’Université de Montréal (CA)
Funders
Harvard Catalyst, Wellcome Trust, National Institutes of Health, National Institute of Allergy and Infectious Diseases